{
  "data": {
    "indicator": {
      "slug": "ctgov-kras-phase-3-trials",
      "name": "Phase 3 KRAS and RAS inhibitor trials",
      "definition": "Count of interventional studies whose record names a KRAS or RAS inhibitor (G12C, G12D, pan-KRAS and pan-RAS agents) registered as Phase 3 or Phase 2/3, any start date.",
      "unit": "count",
      "scale": "1",
      "default_unit": "count",
      "default_scale": "1"
    },
    "scale": "1",
    "unit": "count",
    "region": {
      "code": "GLOBAL",
      "name": "Global",
      "type": "world"
    },
    "points": [
      {
        "period_start": "2026-09-27",
        "period_label": "as of 27 Sep 2026",
        "value": 36,
        "scale": "1",
        "unit": "count",
        "value_type": "actual",
        "statistic_id": "stat_TZF5V3BMAC38GB3QNZETZQMTXH",
        "url": "https://statorigin.org/stat/stat_TZF5V3BMAC38GB3QNZETZQMTXH",
        "source_org": "ClinicalTrials.gov",
        "source": {
          "org": "ClinicalTrials.gov (U.S. National Library of Medicine)",
          "org_short_name": "ClinicalTrials.gov",
          "document_title": "ClinicalTrials.gov study count: Interventional studies whose record names a KRAS or RAS inhibitor (G12C, G12D, pan-KRAS and pan-RAS agents) registered as Phase 3 (including Phase 2/3), any start date, on 2026-09-27",
          "document_url": "https://clinicaltrials.gov/api/v2/studies?query.term=sotorasib%20OR%20adagrasib%20OR%20divarasib%20OR%20daraxonrasib%20OR%20RMC-6236%20OR%20elironrasib%20OR%20RMC-6291%20OR%20zoldonrasib%20OR%20RMC-9805%20OR%20olomorasib%20OR%20garsorasib%20OR%20fulzerasib%20OR%20glecirasib%20OR%20MRTX1133%20OR%20%22KRAS%20G12C%20inhibitor%22%20OR%20%22KRAS%20G12D%20inhibitor%22%20OR%20%22pan-KRAS%22%20OR%20%22pan-RAS%22%20OR%20%22KRAS%20inhibitor%22%20OR%20opnurasib%20OR%20D-1553%20OR%20LY3537982%20OR%20HRS-4642%20OR%20INCB161734%20OR%20ASP3082%20OR%20setidegrasib%20OR%20%22AMG%20510%22%20OR%20MRTX849%20OR%20GDC-6036%20OR%20G12D%20OR%20GFH925%20OR%20IBI351%20OR%20JAB-21822&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BPhase%5DPHASE3&countTotal=true&pageSize=1&fields=NCTId",
          "locator": "totalCount field of the API response. Query: Interventional studies whose record names a KRAS or RAS inhibitor (G12C, G12D, pan-KRAS and pan-RAS agents) registered as Phase 3 (including Phase 2/3), any start date, on 2026-09-27.",
          "published_date": null
        }
      }
    ],
    "available_regions": [
      "GLOBAL"
    ]
  },
  "meta": {
    "attribution": "Data from StatOrigin (https://statorigin.org), CC BY 4.0. Attribution required.",
    "license": "https://creativecommons.org/licenses/by/4.0/",
    "docs": "https://statorigin.org/docs/api",
    "total": 1
  }
}